MIRA制药公司报告Ketamir-2,一种非致瘾氯胺酮模拟物,在早期试验中是安全和有效的,计划推进下一阶段的研究。 MIRA Pharmaceuticals reports Ketamir-2, a non-addictive ketamine analog, was safe and effective in early trials, with plans to advance to next-phase studies.

MIRA制药公司报告说,第一阶段对Ketamir-2进行的单升剂量研究取得了积极的上行结果,该研究是用于神经和神经精神病症状的口服、非预定氯胺酮类比。 MIRA Pharmaceuticals reported positive topline results from a Phase 1 single ascending dose study of Ketamir-2, an oral, non-scheduled ketamine analog for neurologic and neuropsychiatric conditions. 在四个剂量组(50毫克至600毫克)的32名健康志愿者中(50毫克至600毫克),Ketamir-2是安全的,得到很好的容忍,没有严重不良事件、剂量限制毒性或中枢神经系统重大副作用。 In 32 healthy volunteers across four dose groups (50 mg to 600 mg), Ketamir-2 was safe and well tolerated, with no serious adverse events, dose-limiting toxicities, or significant central nervous system side effects. 该药物表现出快速、可预测的吸收,在1至2小时内达到最高血位,并有一个有利的药用动力学特征,支持了一次每日剂量。 The drug showed rapid, predictable absorption, reaching peak blood levels in 1–2 hours, and a favorable pharmacokinetic profile supporting once-daily dosing. 与口服氯胺酮不同,Ketamir-2展示了剂量比例的接触,没有分离效应。 Unlike oral ketamine, Ketamir-2 demonstrated dose-proportional exposure and no dissociative effects. 根据这些调查结果,MIRA正在推进到第一阶段的多次上升剂量部分,随后对神经病痛患者进行了第二阶段a研究。 Based on these findings, MIRA is advancing to the multiple ascending dose portion of Phase 1, followed by a Phase 2a study in patients with neuropathic pain. 该公司强调Ketamir-2公司作为非惩罚性治疗的潜力,并正在探讨建立伙伴关系以加速发展。 The company emphasized Ketamir-2’s potential as a non-addictive treatment and is exploring partnerships to accelerate development.